| Volume 20 • Issue 2 |
January 22, 2020 |
|
|
|
|
 |
| |
DISCONTINUATION OF TUSSIONEX® SUSPENSION
|
|
|
Sanofi-aventis Canada Inc. would like to inform you that Tussionex® suspension (Resinated hydrocodone with phenyltoloxamine) is discontinued due to a business decision.
READ MORE
|
 |
|
|
 |
| |
TEMPORARY SHORTAGE OF FASTURTEC
|
|
|
Sanofi Genzyme would like to inform you of an anticipated market shortage in Canada of FASTURTEC, 1.5 mg/ vial (rasburicase).
READ MORE
|
 |
|
|
 |
| |
BE AMONG THE FIRST TO LEARN ABOUT RINVOQ – NOW AVAILABLE IN CANADA
|
|
|
AbbVie is proud to announce that RINVOQ is now available in Canada. For ordering information,
CLICK HERE
|
 |
|
|
| |
INTRODUCING AKLIEF® (TRIFAROTENE 50 MCG/G) CREAM
|
|
|
The first topical retinoid indicated for the treatment of truncal and facial acne*.
*Comparative clinical significance is unknown.
READ MORE
|
 |
|
|
 |
| |
NEW – BAQSIMI: NOW AVAILABLE IN CANADA
|
|
|
In a severe hypoglycemia emergency, BAQSIMI, a portable dry nasal powder glucagon, is comparable in efficacy to injectable glucagon and successfully administered by trained and untrained persons. DIN: 02492415 UPC: 773007000730.
READ MORE
|
 |
|
|
|
|
| |
TRUSTED BY DOCTORS AND PHARMACISTS FOR OVER 55 YEARS
|
|
|
Capsules and Suspension to help your iron needs…
READ MORE
|
 |
|
| |
COLD-FX® IS AN EVIDENCE-BASED PRODUCT
|
|
|
The safety and efficacy of COLD-FX® has been assessed with more than…
READ MORE
|
 |
|
|
|
|
